Adults 50 and older who received doses of both the Pfizer/BioNTech and AstraZeneca/Oxford COVID-19 vaccines reported more mild and moderate side effects than those given only one type of two-dose vaccine, according to a study yesterday in The Lancet.The descriptive findings could help inform countries' decisions about how to proceed with second doses after suspending or stopping orders of the AstraZeneca vaccine amid reports of rare but serious blood clots, the authors noted.
The European Union, for example, recently announced that it would not renew its contract with AstraZeneca beyond June and had signed a new contract with Pfizer.The preliminary research, out of the Com-COV study of vaccine second doses led by University of Oxford